FDA Brief

Warning letters Drugs

FDA warning letter to

Fulijaya Manufacturing SDN. BHD.

High riskIssued Jan 14Posted Jan 27Center for Drug Evaluation and Research (CDER)

Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

What happened

FDA inspected the Kulim, Kedah, Malaysia facility from July 14 to 18, 2025. It found that laboratory records lacked complete raw data for microbiological release and stability testing before May 2025, and a company representative said logbooks were not available. FDA also found no growth promotion testing of microbiological media, no testing of a component for Burkholderia cepacia complex, and stability testing that did not test all active ingredients or impurities.

What FDA found

  1. The firm did not keep complete original laboratory records, including raw data for microbiological release and stability tests.

    21 CFR 211.194(a)
  2. The firm lacked sound laboratory controls: it did not test microbiological media for growth promotion before use and did not test a component for Burkholderia cepacia complex.

    21 CFR 211.160(b)
  3. The firm lacked adequate stability data: it did not test each active ingredient at every planned timepoint and did not set impurity limits or test for impurities.

    21 CFR 211.166(a)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with corrective actions and supporting assessments, including data-integrity and stability remediation and independent laboratory review. If it cannot finish in that time, it must explain the delay and give a completion schedule.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • US companies that rely on Fulijaya as a drug manufacturer
  • quality teams that use contract laboratories for microbial or stability testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk